2 results  1 of 1 

1 Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years
Byung Wook Yoo, Chang Oh Kim, Allen Izu, Ashwani Kumar Arora, Esther Heijnen
Infect Chemother.2018;50(4):301-310.   Published online 2018 December 20     DOI: http://dx.doi.org/10.3947/ic.2018.50.4.301
      
2 Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
Theodore F Tsai
Infect Chemother.2013;45(2):159-174.   Published online 2013 June 26     DOI: http://dx.doi.org/10.3947/ic.2013.45.2.159
      

 1 of 1